Positions

Selected Publications

Academic Article

Year Title Altmetric
2018 Caregiver priorities for endpoints to evaluate treatments for Prader-Willi syndrome: a best–worst scalingJournal of Medical Economics (JME).  21:1230-1237. 2018
2018 High levels of caregiver burden in Prader-Willi syndromePLoS ONE.  13. 2018
2018 Use of Mobile Devices to Measure Outcomes in Clinical Research, 2010-2016: A Systematic Literature Review.Digital Biomarkers.  2:11-30. 2018
2017 Toxicity and Pharmacokinetic Profile for Single-Dose Injection of ABY-029: a Fluorescent Anti-EGFR Synthetic Affibody Molecule for Human UseClinical Positron Imaging.  19:512-521. 2017
2016 Prader-Willi syndrome mental health research strategy workshop proceedings: the state of the science and future directionsOrphanet Journal of Rare Diseases.  11:1-7. 2016
2016 The High Direct Medical Costs of Prader-Willi SyndromeJournal of Pediatrics.  175:137-143. 2016
2016 Vision 20/20: Molecular-guided surgical oncology based upon tumor metabolism or immunologic phenotype: Technological pathways for point of care imaging and interventionMedical Physics.  43:3143-3156. 2016
2016 Single dose GLP toxicity and biodistribution study of a conditionally replicative adenovirus vector, CRAd-S-pk7, administered by intracerebral injection to Syrian hamstersJournal of Translational Medicine.  14. 2016
2015 Safety and tumor specificity of cetuximab-IRDye800 for surgical navigation in head and neck cancerClinical Cancer Research.  21:3658-3666. 2015
2015 Medication Trials for Hyperphagia and Food-Related Behaviors in Prader-Willi Syndrome.Diseases.  3:78-85. 2015
2015 Advancing molecular-guided surgery through probe development and testing in a moderate cost evaluation pipelineProgress in Biomedical Optics and Imaging - Proceedings of SPIE.  9311. 2015
2014 IND-Directed Safety and Biodistribution Study of Intravenously Injected Cetuximab-IRDye800 in Cynomolgus MacaquesClinical Positron Imaging.  17:49-57. 2014
2009 A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivoVaccine.  27:7116-7124. 2009
2007 Whole genome microarray analysis of gene expression in Prader-Willi syndromeAmerican Journal of Medical Genetics.  143:430-442. 2007
2006 DNA vaccines for cancerFrontiers in Bioscience.  11:1189-1198. 2006
2006 Enhanced transduction of mouse bone marrow-derived dendritic cells by repetitive infection with self-complementary adeno-associated virus 6 combined with immunostimulatory ligandsGene Therapy.  13:29-39. 2006
2005 A DNA vaccine encoding genetic fusions of carcinoembryonic antigen (CEA) and granulocyte/macrophage colony-stimulating factor (GM-CSF)Vaccine.  23:1273-1283. 2005
2005 Antitumor activity of the intratumoral injection of fowlpox vectors expressing a triad of costimulatory molecules and granulocyte/macrophage colony stimulating factor in mesotheliomaInternational Journal of Cancer.  113:406-414. 2005
2005 Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanomaHuman Gene Therapy.  16:91-100. 2005
2004 Mesothelin: A new target for immunotherapy (multiple letter) [1]Clinical Cancer Research.  10:8751-8752. 2004
2004 Some remarks on the somatic expression of sperm protein 17 [1] (multiple letters)International Journal of Cancer.  111:972-974. 2004
2004 Augmentation of antitumor activity of a recombinant adeno-associated virus carcinoembryonic antigen vaccine with plasmid adjuvantHuman Gene Therapy.  15:856-864. 2004
2004 Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancerInternational Journal of Cancer.  111:303-309. 2004
2004 Characterization of human mesothelin transcripts in ovarian and pancreatic cancerBMC Cancer.  4. 2004
2004 Expression of sperm protein 17 (Sp17) in ovarian cancerInternational Journal of Cancer.  108:805-811. 2004
2003 CD40 is expressed on ovarian cancer cells and can be utilized for targeting adenovirusesClinical Cancer Research.  9:619-624. 2003
2002 Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapyHuman Gene Therapy.  13:1505-1514. 2002
2002 Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patientsClinical Cancer Research.  8:2782-2787. 2002
2001 Expression of human endogenous retrovirus K envelope transcripts in human breast cancerClinical Cancer Research.  7:1553-1560. 2001
2000 Gene therapy for carcinoma of the breast genetic immunotherapyBreast Cancer Research.  2:15-21. 2000
2000 A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): A phase I trialClinical Cancer Research.  6:3081-3087. 2000
2000 Adenoviral-mediated suicide gene therapy for ovarian cancerMolecular Therapy.  2:524-530. 2000
2000 Development of a Polynucleotide Vaccine from Melanoma Antigen Recognized by T Cells-1 and Recombinant Protein from Melanoma Antigen Recognized by T Cells-1 for Melanoma Vaccine Clinical TrialsJournal of Immunotherapy.  23:379-386. 2000
2000 Ovarian cancer gene therapy: Repeated treatment with thymidine kinase in an adenovirus vector and ganciclovir improves survival in a novel immunocompetent murine modelAmerican Journal of Obstetrics and Gynecology.  182:553-559. 2000
2000 SEREX analysis for tumor antigen identification in a mouse model of adenocarcinomaCancer Gene Therapy.  7:446-455. 2000
2000 Using a tropism-modified adenoviral vector to circumvent inhibitory factors in ascites fluidHuman Gene Therapy.  11:1657-1669. 2000
1999 Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vectorClinical Cancer Research.  5:2571-2579. 1999
1999 Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinomaArchives of Otolaryngology Head and Neck Surgery.  125:856-863. 1999
1998 Polynucleotide immunization of nonhuman primates against carcinoembryonic antigenClinical Cancer Research.  4:2903-2912. 1998
1998 Cystic fibrosis transmembrane conductance regulator (CFTR) anion binding as a probe of the poreBiophysical Journal.  74:1320-1332. 1998
1997 CFTR activation: Additive effects of stimulatory and inhibitory phosphorylation sites in the R domainAJP - Lung Cellular and Molecular Physiology.  273. 1997
1997 CFTR activation: additive effects of stimulatory and inhibitory phosphorylation sites in the R domain.American Journal of Physiology.  273:L127-L133. 1997
1997 Gene therapy strategies for carcinoma of the breastBreast Cancer Research and Treatment.  44:93-114. 1997
1997 Epithelial localization of a reptilian Na+/H+ exchanger homologous to NHE-1.American Journal of Physiology.  272:G1594-G1606. 1997
1997 Epithelial localization of a reptilian Na+/H+ exchanger homologous to NHE-1AJP - Gastrointestinal and Liver Physiology.  272. 1997
1997 Identification of a splice site mutation (2789 + 5 G>A) associated with small amounts of normal CFTR mRNA and mild cystic fibrosisHuman Mutation.  9:332-338. 1997
1997 An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2Gene Therapy.  4:317-322. 1997
1997 Identification of a splice site mutation (2789 +5 G > A) associated with small amounts of normal CFTR mRNA and mild cystic fibrosis.Human Mutation.  9:332-338. 1997
1997 Incorporation of β-globin untranslated regions into a Sindbis virus vector for augmentation of heterologous mRNA expressionGene Therapy.  4:624-627. 1997
1996 E1A RNA transcripts amplify adenovirus-mediated tumor reductionGene Therapy.  3:1021-1025. 1996
1996 Novel missense mutation (G314R) in a cystic fibrosis patient with hepatic failureHuman Mutation.  7:151-154. 1996
1996 Novel missense mutation (G314R) in a cystic fibrosis patient with hepatic failure.Human Mutation.  7:151-154. 1996
1995 Missense mutation (G480C) in the CFTR gene associated with protein mislocalization but normal chloride channel activityHuman Molecular Genetics.  4:269-273. 1995
1994 Identification of a CFTR frameshift mutation (1013 delAA) in trans to ΔF508 in a pancreatic sufficient cystic fibrosis patientHuman Molecular Genetics.  3:2063-2064. 1994
1994 Localization of cystic fibrosis transmembrane conductance regulator mRNA in the human gastrointestinal tract by in situ hybridizationJournal of Clinical Investigation.  93:347-354. 1994
1993 Molecular basis of defective anion transport in L cells expressing recombinant forms of CFTRHuman Molecular Genetics.  2:1253-1261. 1993
1993 Expression of an abundant alternatively spliced form of the cystic fibrosis transmembrane conductance regulator (CFTR) gene is not associated with a camp-activated chloride conductanceHuman Molecular Genetics.  2:225-230. 1993
1993 Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cellsGastroenterology.  105:1857-1864. 1993
1993 Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissuesNature Genetics.  5:259-265. 1993
1992 Characterization of an intron 12 splice donor mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) geneHuman Mutation.  1:380-387. 1992
1991 Cystic fibrosis gene mutation in two sisters with mild disease and normal sweat electrolyte levelsNew England Journal of Medicine.  325:1630-1634. 1991
1991 Evidence for tau expression in cells of monocyte lineage and its in vitro phosphorylation by v-fms kinaseOncogene.  6:1085-1087. 1991
1991 Two frameshift mutations in the cystic fibrosis geneAmerican Journal of Human Genetics.  48:227-231. 1991
1991 Chloride conductance expressed by ΔF508 and other mutant CFTRs in xenopus oocytesScience.  254:1797-1799. 1991
1990 Polyacrylamide gel analysis of polypeptides in gene transfer cell linesSomatic Cell and Molecular Genetics.  16:341-349. 1990

Chapter

Year Title Altmetric
2017 Cancer Genetics and Biology.  41-46. 2017

Education And Training

  • Doctor of Philosophy in Medical Genetics, University of Alabama at Birmingham 1989
  • Full Name

  • Theresa Strong